Vlado Perkovic

Jan 23, 2025 | onlinelibrary.wiley.com | Safia Chatur |Muthiah Vaduganathan |Robert Fletcher |Vlado Perkovic

Introduction Patients with type 2 diabetes face heightened risk for the development of comorbid cardiovascular and kidney disease including heart failure (HF).1 The sodium–glucose cotransporter 2 (SGLT2) inhibitor canagliflozin has been shown to reduce the risk of HF hospitalization or cardiovascular death among patients with type 2 diabetes at high cardiovascular and kidney risk across a broad range of patient subgroups in the CANVAS and CREDENCE trials, respectively.2, 3 Loop diuretics are...

Jul 12, 2024 | radcliffecardiology.com | Vlado Perkovic |Kevin Cheng |Jonathan Hill |Pam R Taub

ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153). The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median follow-up period was 3.4 years, as the trial was stopped early at a prespecified interim analysis.